Latest gastrointestinal stromal tumor Stories
WAYNE, N.J., May 10, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S.
TUEBINGEN, Germany, April 11, 2011 /PRNewswire/ -- immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT = IMA901 Multi-Peptide vaccine Randomized INTernational study) with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma. The pivotal Phase III study will evaluate as the primary endpoint...
WAYNE, N.J., Feb. 4, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S.
NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Pfizer Inc.
NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- Pfizer Inc.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract.
New breakthrough treatments for the most common cancers could soon come from cutting-edge research into some of the world's rarest tumors.
Researchers are able to predict and reverse resistance to a commonly used treatment.
A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract.
- Inward knowledge; understanding; conscience.